Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLand & ImprovementsLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Icu Medical (ICUI) Raw Materials (2020 - 2025)

Icu Medical's Raw Materials history spans 6 years, with the latest figure at $29.8 million for Q1 2025.

  • For the quarter ending Q1 2025, Raw Materials fell 37.09% year-over-year to $29.8 million, compared with a TTM value of $29.8 million through Mar 2025, down 37.09%, and an annual FY2024 reading of $28.6 million, down 38.42% over the prior year.
  • Raw Materials for Q1 2025 was $29.8 million at Icu Medical, up from $28.6 million in the prior quarter.
  • The five-year high for Raw Materials was $50.3 million in Q3 2024, with the low at $26.5 million in Q3 2021.
  • Average Raw Materials over 5 years is $38.3 million, with a median of $38.5 million recorded in 2022.
  • Year-over-year, Raw Materials soared 39.46% in 2022 and then plummeted 38.42% in 2024.
  • Tracing ICUI's Raw Materials over 5 years: stood at $28.5 million in 2021, then surged by 34.9% to $38.5 million in 2022, then grew by 20.78% to $46.5 million in 2023, then plummeted by 38.42% to $28.6 million in 2024, then rose by 4.17% to $29.8 million in 2025.
  • Per Business Quant, the three most recent readings for ICUI's Raw Materials are $29.8 million (Q1 2025), $28.6 million (Q4 2024), and $50.3 million (Q3 2024).